Introduction to Acral Lentiginous Melanoma (ALM)

Acral Lentiginous Melanoma (ALM) stands as a distinct and often misunderstood entity within the spectrum of skin cancers. Unlike its more common counterparts, such as superficial spreading melanoma, ALM originates on the body's acral (non-hair-bearing) surfaces—specifically the palms of the hands, the soles of the feet, and beneath the nail beds (subungual region). This unique location is the primary differentiator. While most melanomas are strongly linked to cumulative ultraviolet (UV) radiation exposure from the sun, ALM arises in areas largely shielded from the sun. This suggests that its pathogenesis involves different genetic and environmental factors, making it a critical area of ongoing research. Its rarity and atypical presentation often lead to delays in diagnosis, which can significantly impact prognosis.

In terms of prevalence, ALM is the rarest major subtype of melanoma in Caucasian populations, accounting for only 2-3% of all melanoma cases. However, its epidemiological profile shifts dramatically across ethnicities. It is the most common form of melanoma in people with darker skin tones, including individuals of African, Asian, and Hispanic descent. In Hong Kong, for instance, melanoma is less common than in Western countries, but when it does occur, acral lentiginous melanoma represents a significant proportion of cases. A study based on data from the Hong Kong Cancer Registry highlighted that ALM is a prominent subtype among the local Chinese population, underscoring the importance of awareness in non-Caucasian demographics. Risk factors are not fully understood but are believed to involve genetic mutations (like amplifications in the CCND1 gene) and possible trauma or pressure, though the latter is not conclusively proven.

The common locations—palms, soles, and nail beds—are areas frequently subjected to pressure and friction. On the sole, a melanoma acrale lentigginoso piede may initially be mistaken for a bruise, wart, or fungal infection. A classic early sign can be a longitudinal brown or black streak in a fingernail or toenail (melanonychia striata), which, if new, widening, or appearing in a single digit in an adult, warrants immediate dermatological evaluation. Recognizing that melanoma can occur in these sun-protected sites is the first and most crucial step toward early detection.

Identifying ALM: Symptoms and Early Detection

Early detection of ALM is challenging but paramount for successful treatment. The standard ABCDE rule for melanoma (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution) applies but must be adapted with nuance for acral sites. Asymmetry may be present when one half of the lesion does not match the other. Borders are often irregular, scalloped, or poorly defined. Color can be particularly telling; ALM often displays a mix of tan, brown, black, and sometimes red, white, or blue areas. Diameter is a useful guide, but early ALM can be smaller than 6mm, so any new, changing, or suspicious spot should be examined regardless of size. The "E" for Evolution is arguably the most critical—any change in size, shape, color, or symptoms (like itching or bleeding) is a red flag.

A visual guide is indispensable. Early ALM on the sole might appear as an irregular, darkly pigmented patch with uneven borders. It may follow the skin lines (dermatoglyphics) in its early radial growth phase. Under the nail, it typically presents as a pigmented band that widens over time and may involve the surrounding skin (Hutchinson's sign), a highly suggestive feature of subungual melanoma. While we cannot embed images here, searching for melanoma acrale lentigginoso foto online from reputable medical sources (like dermatology atlases or academic hospital websites) can provide valuable visual references. However, self-diagnosis via the internet is strongly discouraged; these resources should only serve to educate and prompt a professional consultation.

The importance of regular self-exams and professional skin checks cannot be overstated. For self-exams, use a well-lit room and a mirror, or ask a partner for help. Pay meticulous attention to the entire body, including the often-overlooked acral surfaces: inspect between toes and fingers, the entire sole and heel, the palms, and under each nail. Professional skin checks by a dermatologist are recommended annually for the general public and more frequently for high-risk individuals. Dermatologists are trained to recognize subtle signs and use tools like dermoscopy, which is especially crucial for evaluating pigmented lesions on acral skin.

Diagnosis and Staging of ALM

The journey to a definitive ALM diagnosis begins with clinical suspicion and is confirmed through histopathology. If a lesion is deemed suspicious, a biopsy is performed. For suspected ALM, an excisional biopsy (removing the entire lesion with a narrow margin) is preferred when possible to allow for accurate measurement of tumor thickness (Breslow depth), the single most important prognostic factor. Incisional or punch biopsies may be used for larger lesions on functionally sensitive areas.

Dermoscopy, the examination of skin lesions with a dermatoscope, is a non-invasive, in-office technique that has revolutionized the diagnosis of pigmented skin lesions. When evaluating a potential melanoma al dermatoscopio on acral skin, dermatologists look for specific patterns not visible to the naked eye. The key dermoscopic pattern for early ALM on volar skin is the "parallel ridge pattern," where pigment is concentrated on the epidermal ridges (the raised lines of your fingerprints or footprints). This contrasts with benign lesions like melanocytic nevi, which typically show a "parallel furrow pattern" (pigment in the grooves). For nail apparatus melanoma, dermoscopy helps assess the regularity and coloration of the band and the presence of micro-Hutchinson's sign.

Once diagnosed, staging determines the extent of the disease and guides treatment. Melanoma is staged using the American Joint Committee on Cancer (AJCC) TNM system, which evaluates:

• T (Tumor): Based on Breslow thickness (in millimeters) and the presence of ulceration (break in the skin over the tumor).
• N (Nodes): Whether cancer has spread to nearby lymph nodes and how many are involved.
• M (Metastasis): Whether cancer has spread to distant organs like the lungs, liver, or brain.

Stages range from 0 (melanoma in situ, confined to the top layer of skin) to IV (distant metastasis). Prognosis is heavily influenced by the Breslow thickness. For example, a thin melanoma (

Treatment Options for ALM

The cornerstone of treatment for localized ALM is wide surgical excision. The goal is to remove the primary tumor with clear microscopic margins to eliminate all cancer cells. The recommended margin width depends on the tumor's Breslow thickness, as per established guidelines (e.g., 1 cm for tumors up to 2 mm thick). For subungual ALM, this often requires partial or complete amputation of the digit to achieve adequate margins, a functionally and cosmetically significant procedure. In all cases, the priority is complete oncologic removal to prevent local recurrence.

For patients with higher-risk disease (e.g., Stage IIB/C or Stage III), adjuvant (additional) therapy after surgery is standard to reduce the risk of recurrence. The landscape of adjuvant therapy has been transformed by immunotherapy and targeted therapy. Immunotherapy drugs, such as pembrolizumab and nivolumab, work by blocking checkpoints like PD-1, thereby "releasing the brakes" on the patient's own immune system to attack melanoma cells. Targeted therapy is an option for the approximately 10-15% of ALM cases that harbor a KIT mutation (more common in ALM than in other melanoma subtypes). Drugs like imatinib target this specific mutation. These systemic therapies have significantly improved relapse-free and overall survival rates.

For advanced (Stage IV or unresectable Stage III) ALM, treatment focuses on controlling the disease and prolonging life. First-line options typically involve combination immunotherapy or targeted therapy (if a KIT or, more rarely, a BRAF mutation is present). Participation in clinical trials offers access to novel therapies, such as new drug combinations, adoptive cell therapies (like TIL therapy), or oncolytic viruses. Palliative care, an essential component of treatment at any stage, becomes central in advanced disease. It focuses on managing symptoms, controlling pain, and providing psychological, social, and spiritual support to improve the quality of life for both patients and their families.

Living with ALM: Prevention, Support, and Resources

Prevention strategies for ALM differ from those for sun-related melanomas. Since UV exposure is not a primary cause, broad-spectrum sunscreen, while important for overall skin health, is not a specific preventive measure for ALM. The key lies in awareness and early detection. High-risk individuals, including those with a personal or family history of melanoma or darker-skinned individuals, should be particularly vigilant in performing monthly self-exams of their acral skin. Wearing properly fitted shoes to minimize repetitive trauma to the feet is a sensible, though not proven, precaution. Public health initiatives in regions like Hong Kong should focus on educating the public and healthcare providers about the signs of ALM in commonly affected populations.

A diagnosis of ALM can be isolating. Finding support is crucial. Patients and families can benefit from connecting with others who share similar experiences. Reputable organizations provide invaluable resources:

• The Melanoma Research Foundation (MRF): Offers patient guides, webinars, and a community forum.
• Cancer Support Groups: Many hospitals, including those in Hong Kong like the Hong Kong Anti-Cancer Society and patient support services at major oncology centers, offer counseling and support groups.
• Online Communities: Moderated online forums can provide 24/7 peer support, though information should always be verified with a medical team.

The importance of diligent follow-up care cannot be overemphasized. After primary treatment, patients enter a surveillance period that typically lasts for at least 5-10 years. Follow-up schedules are tailored to the initial stage but generally include regular physical exams, skin checks, and sometimes imaging tests to monitor for recurrence or new primary melanomas. Patients must also be educated on the signs of potential metastasis (e.g., new lumps, persistent cough, headaches) to report immediately. This proactive, long-term partnership between the patient and their oncology-dermatology team is the best strategy for ensuring ongoing health and early intervention if needed.